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Purpose: Glaucoma is the second leading cause of blindness. The ultimate cause of vision loss in glaucoma is thought to
be retinal ganglion cell (RGC) death. Neuroprotection of RGC is therefore an important goal of glaucoma therapy. Several
lines of evidence suggest that pigment epithelium derived factor (PEDF) is a potent anti-angiogenic, neuroprotective, and
anti-inflammatory factor for neurons. In this study, we examined the potential role of PEDF in protection of RGC in the
DBA/2J mouse, an animal model of inherited glaucoma.
Methods: DBA/2J mice at two months of age were transfected intravitreally with adeno-associated virus (AAV)-PEDF
or AAV-green fluorescent protein (AAV-GFP). RGC and nerve fiber layer protection were evaluated in retinal cross
sections. Biochemical alterations in the retinas of DBA/2J mice in response to intravitreal transfection of PEDF were also
examined by reverse transcriptase PCR (RT–PCR) and western blot. Cellular localization of PEDF and glial fibrillary
acidic protein (GFAP) was determined by immunohistochemistry. Visual acuity was determined by optomotor testing.
Results: PEDF protein levels in the retina and optic nerves of DBA/2J mice declined with age. The expression of tumor
necrosis factor (TNF), GFAP, and interleukin-18 (IL-18) increased with age in the retina and optic nerve of DBA/2J mice.
Intravitreal PEDF transfection in DBS/2J mice reduced loss of RGC and nerve fiber layer, delayed vision loss, and reduced
TNF, IL-18, and GFAP expression in the retina and optic nerve.
Conclusions: Transduced PEDF potently and efficaciously reduces RGC loss and vision decline in DBA/2J mice, possibly
via the reduction of TNF and IL-18, and downregulation of GFAP. The anti-inflammatory effect of PEDF represents a
novel approach to the prevention of glaucomatous RGC death.
Pigment  epithelium-derived  factor  (PEDF),  a  50  kDa
glycoprotein, belongs to the serine protease inhibitor (serpin)
superfamily. PEDF is thought to be both neurotrophic and
anti-angiogenic.  The  neuroprotective  capacity  of  PEDF
protein has been documented by extensive experimental data
both in vitro and in vivo. PEDF can significantly prevent
glutamate-induced apoptotic cell death in cerebellar granular
cells  [1,2],  hippocampal  neurons  [3],  and  spinal  motor
neurons [4]. PEDF protects retinal photoreceptor cells from
light  damage  in  the  rat  [5],  delays  progression  of
photoreceptor  degeneration,  and  reduces  apoptosis  of
photoreceptor cells in retinal degeneration slow (rds) mutant
mice [6]. PEDF has also been shown to protect adult rat retinal
ganglion  cells  (RGC)  from  glutamate-  and  trophic  factor
withdrawal-mediated  cytotoxicity  [7],  and  reduce  retinal
ischemia-induced RGC loss [8,9]. In addition, PEDF has been
recognized as an important endogenous anti-inflammatory
factor  [10].  Vitreous  levels  of  PEDF  were  significantly
decreased  in  proliferative  diabetic  retinopathy,  suggesting
that  reduced  PEDF  in  the  retina  may  contribute  to  the
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pathogenesis  of  diabetic  retinopathy,  perhaps  by
augmentation of retinal inflammation [10,11].
Glaucoma, the second leading causes of blindness, is
characterized by loss of RGC and excavation of the optic
nerve head [12]. At the present time, medical treatments of
glaucoma include the non-specific reduction of intraocular
pressure  (IOP)  with  medications  that  suppress  aqueous
production or enhance aqueous outflow, laser trabeculoplasty,
and  filtering  surgery.  Although  little  is  known  about  the
molecular/biochemical  mechanism(s)  underlying  the
glaucoma family of disorders, RGC degeneration represents
a  final  step  in  glaucomatous  vision  loss.  Therefore,
neuroprotection of RGC is a critical element in management
of the disease [13].
Recent and quickly accumulating evidence demonstrates
that the degeneration of RGC in glaucoma is associated with
low-grade, subclinical inflammation. Increased levels of pro-
inflammatory mediators such as tumor necrosis factor (TNF)
have  been  demonstrated  in  glaucoma  patients  [14].  In
glaucomatous  eyes,  the  expression  of  TNF  and  TNF
receptor-1 was upregulated in the retina and optic nerve head
[14,15]. It has been reported that the expression of TNF and
TNF  receptor-1  parallel  the  progression  of  optic  nerve
degeneration [16]. Moreover, a functional blockade of TNF
with a TNF blocking antibody or deletion of the gene encoding
TNF  in  mice  completely  prevented  ocular  hypertension-
induced oligodendrocyte degeneration and the secondary loss
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438of RGC. These results support the notion that inflammation
plays an important role in the development and progression
of glaucoma.
The DBA/2J mouse has been described as an animal
model for human inherited glaucoma [17,18]. This mouse
strain  develops  several  hallmarks  of  human  pigmentary
glaucoma  including  iris  atrophy,  pigment  dispersion,
peripheral anterior synechiae, elevated IOP, retinal ganglion
cell loss, and optic nerve head excavation [17,19,20]. In our
previous  work  with  DBA/2J  mice,  we  demonstrated  a
correlation  between  elevated  expression  of  interleukin-18
(IL-18) and the death of RGC [21]. We also showed age
dependent decreases in PEDF gene expression and protein in
the  iris/ciliary  body  and  aqueous  humor,  respectively.  In
human patients with advanced glaucoma, intraocular PEDF is
significantly lower than in those with cataract alone [8]. It has
been suggested that lower levels of PEDF in aqueous humor
of eyes with neuroretinal dystrophy – including those with
advanced glaucoma – may be related to the loss of the RGC
or  pigment  epithelium  cells  that  synthesize  PEDF  [8,22].
Furthermore, exogenous PEDF protects RGC from pressure-
induced ischemia [9,23]. However, the mechanisms for the
protective effect of PEDF in the glaucoma are undefined.
In the present study, we make several novel observations.
First, PEDF protein levels in the retina and optic nerve of
DBA/2J mice decrease significantly with age in comparison
to C57BL/6J (control) mice. Second, the expression of TNF,
IL-18, and glial fibrillary acidic protein (GFAP) in the retina
and optic nerve increases with age. Third, PEDF transduction
reduces the loss of RGC and nerve fiber layer, delays vision
loss, and leads to reduced TNF, IL-18, and GFAP in the retina
and optic nerve of DBA/2J mice.
METHODS
Animals: The DBA/2J and C57BL/6J mice used in this study
were purchased from Jackson Laboratory (Bar Harbor, ME).
All animals were born and raised in a 12 h on versus 12 h off
cyclic  light  environment  at  an  illumination  of  50–60  lx.
Animals  were  cared  for  and  handled  according  to  the
Association  for  Research  in  Vision  and  Ophthalmology
statement for the use of animals in vision and ophthalmic
research and with approval of the University of Oklahoma
Health Sciences Center (Oklahoma City, OK) IACUC.
Identification of retinal ganglion cells by retrograde labeling:
The  neuronal  tracer  4-di-10-ASP,  a  long-chain
dialkylcarbocyanine, is widely used to label living tissues, and
with injection of 4-di-10-ASP into the superior colliculus, will
label RGC by retrograde axoplasmic transport [24]. It has
been shown that 7 days after injection of 4-di-10-ASP, more
than 80% of the RGC are labeled [25]. We used 4-di-10-ASP
(Molecular Probes, Eugene, OR) to label RGC as previously
described [21]. Briefly, 4 weeks-old mice were anesthetized
by intraperitoneal administration of a mixture of xylazine and
ketamine. The skin over the cranium was incised, and the skull
was exposed. Holes ~1 mm in diameter were drilled in the
skull 4 mm posterior to the bregma and 1 mm lateral to the
midline on both sides of the midline raphe. These positions
correspond to the superior colliculi as determined from a
stereotactic mouse brain atlas. Retinal ganglion cells project
to the superior colliculus and dorsal lateral geniculate nucleus.
4-di-10-ASP (3 μl of a 25 mg/ml concentration) was injected
through both holes in the superior colliculi region by inserting
a syringe 2 mm deep. The skull openings were then sealed
with a petroleum-based antibiotic ointment. The overlying
skin  was  sutured  and  antibiotic  ointment  was  applied
externally. The mice were euthanized by CO2 inhalation at 1,
6,  and  15  months  following  4-di-10-ASP  administration.
Whole retina flat mounts were prepared by detachment of the
retina at the ora serrata followed by eight radial relaxing
incisions. Imaging of the labeled retinas was performed using
a  digital  camera  and  a  fluorescence  microscope  (Nikon
Instruments, Inc., Melville, NY) at 20X magnification.
Measurement of visual acuity: The Virtual Optomotor System
(OptoMotry;  CerebralMechanics,  Lethbride,  Alberta,
Canada) was used to measure visual acuity as an index of
visual function, as previously shown [26], at 1 to 11 months
of age. The grating spatial acuity was measured starting with
a low spatial frequency (0.1 cyc/deg) sine wave grating at the
same  mean  luminance  and  100%  contrast.  The  spatial
frequency of the grating was incrementally increased until the
animal failed to respond. Each test was performed at least 5
times.  The  threshold  was  identified  as  the  highest  spatial
frequency that mice could track.
Preparation and intravitreous delivery of adeno-associated
virus  expressing  human  PEDF:  Adeno-associated  virus
expressing  human  PEDF  (AAV-PEDF)  has  been  used  to
protect neurons in animal models [27-29]. AAV-PEDF was
constructed by cloning a full-length human PEDF cDNA
under  the  control  of  the  CMV  promoter.  The  construct
sequence  was  confirmed  by  DNA  sequencing  (Oklahoma
Medical  Research  Foundation,  Oklahoma  City,  OK).  A
control virus containing a green fluorescent protein cDNA
under the same promoter (AAV-GFP) was obtained from a
commercial  source  (InVivoGen,  San  Diego,  CA).  AAV-
PEDF and AAV-GFP vector titers were 2.0×1013 particles/ml,
and 2.5×1012 particles/ml, respectively. Intravitreal injection
was performed under general anesthesia after intramuscular
injection of ketamine (85 mg/kg) and xylazine (14 mg/kg).
Anesthetic drops (0.5% proparacaine hydrochloride; Alcon,
Fort Worth, TX) were also applied topically to each eye before
injections.  A  30  gauge  hypodermic  needle  was  used  to
perforate the sclera 1 mm behind the limbus. AAV-PEDF (1
μl) was then injected into the left vitreous and AAV-GFP (1
μl) was injected into the right vitreous using a 10 μl Hamilton
Syringe  (Hamilton  Co,  Reno,  NV)  under  an  ophthalmic
operating microscope (Carl Zeiss Meditec, Inc., Thornwood,
NY).  Care  was  taken  not  to  damage  the  lens.  Following
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and withdrawn slowly. Animals with retinal bleeding or lens
injury following the injection procedure were excluded from
the study. Animals were euthanized nine months after the
injection, and eyes rapidly enucleated. Retinas were dissected
free from the choroid and sclera, and whole mounted on a glass
slide. They were fixed briefly in 4% (w/v) paraformaldehyde
in  PBS.  Whole  retina  was  mounted  with  Vectorshield
mounting medium (Vector Laboratories, Inc., Burlingame,
CA).
Semiquantitative  reverse  transcription  (RT)-PCR:  Reverse
transcription RT–PCR was performed as described previously
[30,31]. For RT–PCR, 4 µg RNA was mixed in water with
random hexamers (50 ng/µl) and 10 mM dNTPs heated to
65 °C for 5 min. The 20 µl RT reaction, containing RNA,
primers, 5 mM MgCl2, 10 mM dithiothreitol, 0.5 mM dNTPs,
40 units of RNase inhibitor (RNase OUT), and 50 units of
Superscript  II  reverse  transcriptase  (Invitrogen,  Carlsbad,
CA), was assembled, heated at 42 °C for 1 h and then at 70 °C
for 15 min. After chilling on ice, 2 units of RNase H were
added to each reaction and the mixture was incubated at 37 °C
for 20 min. PCR was performed in 50 µl reaction volumes,
containing 2 µl of cDNA, 2 units of TaqDNA polymerase
(Promega, Madison, WI), 0.2 mM dNTPs, 10 µM each of
forward  and  reverse  primers,  and  1.5  mM  MgCl2.
Amplification cycles were: one cycle at 94 °C for 3 min,
followed by 35 cycles of 94 °C for 20 s, 58 °C for 45 s, and
72 °C for 1 min, terminating with 72 °C for 10 min. The
amplification products were run on 1% agarose gel containing
10ng/ml ethidium bromides and visualized under UV light.
PEDF, TNF, and IL-18 gene expression were examined by
semi-quantative RT–PCR using the following primers: PEDF
(AF017057) Forward: TGA TCA CCA ACC CTG ACA TCC
ACA, Reverse: GCT GGG CAA TCT TGC AGT TGA GAT;
TNF (NM_013693) Forward: ACA CCG TCA GCC GAT
TTG CTA TCT, Reverse: TGG ACA TTC GAG GCT CCA
GTG AAT; IL-18 (NM_008360) Forward: GAC AAC TTT
GGC CGA CTT CAC TGT, Reverse: CAC AAG GCG CAT
GTG TGC TAA TCA.
Western blot analysis: Western blot analysis was performed
as  described  previously  [32,33].  Retinal  tissues  were
sonicated in 0.0625 M Tris-HCl, pH 6.8, then centrifuged for
15  min  and  the  supernatants  assayed  for  protein  using  a
Bradford assay. Aliquots (10 µg) of the sonicated supernatant
were loaded onto SDS–PAGE mini-gels, electrophoresed, and
transferred to nitrocellulose paper. After transferring, blots
were washed for 2X 10 min in TTBS (0.1% Tween-20 in 20
mM Tris-HCl, pH 7.4, and 410 mM NaCl) and blocked with
10% BSA in TTBS with 5% milk for 2 h at room temperature
or overnight at 4 °C. Blots were incubated with rabbit anti-
IL-18 polyclonal antibody (Millipore, Billerica, MA), rabbit
anti-TNF  polyclonal  antibody  (Millipore,  Billerica,  MA),
rabbit anti-PEDF polyclonal antibody (Santa cruz, Delaware,
CA),  or  rabbit  anti-GFAP  polyclonal  antibody  (Abcam,
Cambridge, MA) for 2 h at room temperature. Following
primary antibody incubations, blots were washed three times
for 5 min each with TTBS, then incubated for 1 h with HRP-
linked secondary antibodies, washed four times for 10 min
each  with  TTBS,  and  developed  by  enhanced
chemiluminescence.  In  some  instances,  membranes  were
stripped by incubation in stripping buffer (62.5 mM Tris-HCl
(pH 6.8), 2% SDS, and 100 mM 2-mercaptoethanol) for 30
min at 50 °C and reused.
Histopathology: Mouse eyes were enucleated, rinsed in PBS,
and fixed with 10% neutral buffered formalin for 24 h at room
temperature. After paraffin embedding, whole eyes were cut
into 5 µm thick sections, mounted on positively charged slides
and  air  dried  overnight.  After  deparaffinization  and
rehydration, slides were stained with hematoxylin and eosin.
Immunohistochemistry: Immunohistochemistry staining was
performed as described previously [34]. Briefly, Eyes were
enucleated  and  then  fixed  with  4%  paraformaldehyde  in
phosphate-buffered saline for 4 h. The whole eye was cut
along the vertical meridian, and tissue sections incubated in
primary  antibodies.  The  secondary  antibody  (Vector
Laboratories, Burlingame, CA) was labeled with fluorescein
isothiocyanate. In control experiments, the primary antibody
was incubated for 2 h at 4 °C with its blocking peptides before
being applied to the section. Sections were photographed and
analyzed with a confocal laser scanning microscope (IX81-
FV500; Olympus, Melville, NY).
Statistical analysis: Each experiment was performed at least
three times. Mean values were calculated and expressed as
means±SD.  Statistical  analyses  were  performed  using
Student's  t-test,  or  ANOVA  with  the  Scheffé  multiple
comparison  test.  A  statistical  difference  was  considered
significant at p<0.05.
RESULTS
Loss of retinal ganglion cells in eyes of DBA/2J mice: RGC
density  was  determined  by  counting  4-di-10-ASP-labeled
RGC in flat whole-mount retinas. Significant loss of RGC was
observed in flat whole-mount retina from DBA/2J mice at 6
months of age (Figure 1B) in comparison to age-matched
control  C57BL/6J  mice  (Figure  1D).  This  loss  of  RGC
appeared to worsen at 15 months of age (Figure 1C). The
morphological difference between ganglion cell layers in the
retina  of  DBA/2J  mice  and  C57BL/6J  control  animals  at
matched age was also compared by histology. Loss of RGC
was apparent in DBA/2J mice at 6 months, and appeared to
have dramatically worsened at 15 months of age (Figures
1F,G, respectively), as compared with retina from C57BL/6J
mice (Figure 1H).
Reduction in PEDF gene and protein expression with age in
eyes of DBA/2J mice: It was previously shown that PEDF
levels in eyes with advanced glaucoma are significantly lower
than in eyes with cataract alone. It has also been suggested
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440that  the  lower  levels  of  PEDF  in  eyes  with  neuroretinal
dystrophy may be related to the loss of the retinal ganglion or
pigment epithelial cells that synthesize PEDF [22]. In DBA/
2J mice, semi-quantitative RT–PCR revealed significantly
decreased retinal PEDF gene expression with age (Figure
2A,B). A decrease of PEDF protein expression with age in
retina from DBA/2J mice was also detected by western blot;
the expression of PEDF was significantly reduced at the age
of 4 months, and this decrease continued to the age of 6 months
(Figure  2C,D).  Western  blot  analysis  also  showed  a
significant reduction of PEDF expression in the optic nerve
of  DBA/2J  mice  at  6  months  of  age  (Figure  2E,F).
Immunohistochemistry demonstrated substantial expression
of PEDF in the RGC and retinal pigment epithelial (RPE)
layers of DBA/2J mice by 1 month of age (Figure 3A). At 6
months of age, decreased PEDF expression in the RGC layer
with  residual  staining  in  the  RPE  layer  of  DBA/2J  mice
(Figure  3B)  was  detected  when  compared  with  the  age-
matched C57BL/6J controls (Figure 3C).
Inflammatory markers in retina and the optic nerve of DBA/
2J mice: TNF is an important inflammatory mediator and is
expressed in the retina and optic nerve head of patients with
glaucoma [15,16,35]. To investigate whether changes in TNF
expression occur in DBA/2J mice, we isolated total RNA and
protein from retina and optic nerve from 1 to 6 months old
mice, and performed RT–PCR and ELISA, respectively. TNF
gene  and  protein  expression  increased  significantly  by  3
months of age in both the retina and optic nerve of DBA/2J
mice compared with control tissue from one month old mice
(Figure 4A-D), and remained elevated through age 6 months.
Significant increases in TNF protein expression was also seen
in optic nerve of DBA/2J mice from 3 to 6 months of age
(Figure 4E,F).
We have previously reported that IL-18 gene expression
in the iris/ciliary body and IL-18 protein in the aqueous humor
of  DBA/2J  mice  are  significantly  increased,  and  further
demonstrated  that  these  increases  occur  before  the
development  of  elevated  IOP  and  loss  of  RGC  [21].  To
determine whether IL-18 is upregulated in the retina and optic
nerve of DBA/2J mice, we performed semi-quantitative RT–
PCR and western blot. mRNA for IL-18 was elevated by 3
months of age, and increased almost twofold by 6 months of
age as compared to IL-18 expression at 1 month of age (Figure
5A,B).  By  western  blot  analysis,  IL-18  protein  increased
approximately twofold at 4–6 months of age (Figure 5C,D).
Upregulation of IL-18 in the optic nerve of DBA/2J mice at 5
and 6 months of age was also found (Figure 5E,F).
Increased GFAP expression in retina and the optic nerve of
DBA/2J mice: Glial cell activation has been proposed as an
important factor contributing to RGC death in glaucoma [36,
37]. Chronic IOP elevation results in significantly increased
GFAP expression in the rat retina and optic nerve [38]. By
immunohistochemistry in DBA/2J mice at 1 month of age,
GFAP expression was mainly localized to the vicinity of the
inner limiting membrane and nerve fiber layer (Figure 6A,B).
Figure 1. Retinal ganglion cell (RGC) degeneration in DBA/2J mice. A: RGC labeled by neurotracer in flat-mounted retina of DBA/2J mice
at 1 month of age. B,C: Substantial loss of RGC in flat-mounted retina from DBA/2J mice at 6 and 15 months of age, respectively. D: Normal
RGC density in whole mount retina from C57BL/6J mice. Red arrows indicate 4-di-10-ASP labeled RGC. E: RGC density in paraffin cross-
section from DBA/2J mice at 1 month of age. F,G: Substantial loss of RGC in retina from DBA/2J mice at 6 and 15 months old, respectively.
H: Normal RGC density in paraffin cross-section from C57BL/6J mice. Black arrows indicate RGC. Insets show higher magnification.
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441However  at  6  months  of  age,  GFAP  expression  was
significantly increased in both retina (Figure 6C) and optic
nerve  (Figure  6D).  Western  blot  analysis  demonstrated
significantly increased GFAP protein in retina and optic nerve
of DBA/2J mice by 3 months of age (Figures 6E-H).
Ocular PEDF gene transfection in DBA/2J mice leads to
increased  intraocular  PEDF  expression,  improved  retinal
ganglion cell survival, and better vision: In situ expression of
GFP  can  be  observed  from  cross-section  or  whole-mount
techniques, whereas the expression of PEDF is detected using
western blot. Injections of AAV vectors encoding GFP or
PEDF  were  performed  in  mice  at  2  months  of  age.  As
demonstrated  by  assessment  of  GFP  expression  in  retinal
whole mount and cross section (Figures 7A,B, respectively)
at 11 months of age (9 months after transfection), the retina
can  be  successfully  transduced  by  intravitreal  injection.
Figure  2.  Reduced  PEDF  gene  and
protein expression in retina and optic
nerve from DBA/2J mice. A: RT–PCR
shows reduced PEDF gene expression
in th retina of DBA/2J mice at 3 and 6
months  of  age.  B:  Graphical
representation of the RT–PCR data in A
after  normalization  with  GAPDH
loading  control  (mean±SD,  n=3).  C:
Reduced  PEDF  protein  expression  in
retina  of  DBA/2J  mice  with  age,  as
detected  by  western  blot.  D:
Densitometric analysis of PEDF protein
expression  in  3  independent
experiments from C after normalization
with  actin  loading  control.  (n=3).  E:
Western blot analysis shows decreased
PEDF protein expression in optic nerve
from DBA/2J mice at 6 months old. F:
Densitometric analysis of PEDF protein
expression  in  3  independent
experiments,  after  normalization  to
actin  loading  control.  Statistical
analyses  for  this  experiment  was
performed  using  ANOVA  with  the
Scheffé  multiple  comparison  test  (the
asterisk indicates a p<0.05).
Figure 3. Immunofluorescent localization of PEDF in retina from DBA/2J and C57BL/6J mice. A: PEDF immunoreactivity localizes to the
RGC and RPE layers in DBA/2J mice at 1 month old. B: Decreased PEDF expression in the RGC layer of DBA/2J mice at 6 months, with
residual staining in the RPE. C: In C56BL/6J mice, PEDF is localized mainly in the RGC and RPE layers. Insets show higher magnification.
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442Transfection of AAV-PEDF resulted in a significant increase
in PEDF protein level in retina from DBA/2J mice at 11
months of age (Figure 7C). The long-term effect of PEDF
gene transfer on RGC survival was also examined. AAV-
PEDF transfected eyes appeared to retain more RGC at 11
months  of  age  (Figure  7D)  than  age-matched  AAV-GFP
transfected eyes (Figure 7E). As an index of visual function,
we compared optomotor acuity in AAV-GFP, AAV-PEDF,
and control transfected mice from 1 to 11 months of age (until
9 months post transfection; Figure 7F). Through 3 months of
age, average acuity was approximately 0.33 cyc/deg in all 3
groups. In AAV-GFP transfected and control DBA/2J mice,
acuity thresholds decreased rapidly thereafter, dropping to
near 0.02 cyc/deg at 11 months of age. In contrast, AAV-
PEDF  transfected  mice  maintained  near  normal  acuity
throughout the study (Figure 7F).
Ocular PEDF transfection reduces TNF and IL-18 expression
in  retina  and  optic  nerve  of  DBA/2J  mice:  To  explore  a
possible link to inflammation in understanding the salutary
effect of PEDF on morphology and visual function in DBA/
2J mice, we next determined levels of TNF and IL-18 in retina
and  optic  nerve  after  AAV-PEDF  transfection.  For  these
experiments, eyes were analyzed at 6 months of age (4 months
after  transfection).  By  RT–PCR,  mRNA  and  protein
expression of both TNF and IL-18 were significantly reduced
in the retina and optic nerve of AAV-PEDF transfected mice
as compared to AAV-GFP mice (Figure 8A-F), suggesting an
anti-inflammatory effect of PEDF in the DBA/2J mice.
PEDF inhibits GFAP overexpression in retina and optic nerve
of DBA/2J mice: GFAP expression has been implicated in the
pathogenesis  of  glaucoma,  and  shown  to  increase  with
progression of glaucoma [39]. We examined the effects of
PEDF transfection on GFAP expression in retina (Figures
9A,C) and optic nerve (Figures 9B,C) of DBA/2J mice at 6
months  of  age.  As  demonstrated  by  western  blot  and
subsequent densitometry, GFAP protein expression in retina
and  optic  nerve  of  PEDF  transfected  DBA/2J  mice  was
significantly reduced compared to that of GFP transfected
mice.
DISCUSSION
We demonstrate in this study of DBA/2J mice that: 1) PEDF
protein levels in retina and optic nerve decrease significantly
with age; 2) expression of TNF, IL-18, and GFAP in retina
and  optic  nerve  increase  with  age;  3)  PEDF  transfection
reduces age-related RGC loss and vision decline; and 4) PEDF
transduction decreases TNF, IL-18, and GFAP expression.
These findings indicate that PEDF potently and efficaciously
Figure  4.  Increased  TNF  gene  and
protein expression in retina and optic
nerve from DBA/2J mice. A: RT–PCR
shows increased TNF gene expression
in retina from DBA/2J mice at 3 and 6
months  of  age.  B:  Graphical
representation  of  3  independent
experiments  in  A  normalized  with
GAPDH  loading  control  (mean±SD).
C: Western blot shows increased TNF
protein expression in retina from DBA/
2J mice at 3 to 6 months of age.  D:
Densitometric analysis of 3 independent
experiments from C, using actin as a
loading control. E: Western blot shows
increased  TNF  protein  expression  in
optic nerve from DBA/2J mice from 3
to 6 months of age. F: Densitometric
analysis  of  three  independent
experiments  in  E.  Statistical  analyses
for this experiment was performed using
ANOVA  with  the  Scheffé  multiple
comparison test (the asterisk indicates a
p<0.05).
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443reduces RGC loss in DBA/2J mice, reduces expression of
TNF and IL-18, and downregulates GFAP.
TNF  is  upregulated  in  several  neurodegenerative
disorders including multiple sclerosis, Parkinson disease, and
Alzheimer  disease  [40]  and  is  increased  in  optic  nerve
microglia  and  astrocytes  of  glaucoma  patients  [15,16,35].
Furthermore, TNF gene polymorphisms increase the risk of
glaucoma [41], suggesting that TNF may contribute to the
pathogenesis  of  the  disease.  Meanwhile,  TNF  is  toxic  to
immunopurified RGC and to RGC in mixed cultures under
conditions of glial stress [42,43]. In vivo, exogenous TNF
leads to loss of oligodendrocytes and a delayed loss of RGC.
Furthermore,  a  functional  blockade  of  TNF  with  TNF
blocking  antibody  or  deletion  of  the  gene  encoding  TNF
completely  prevents  ocular  hypertension-induced
oligodendrocyte degeneration and the secondary loss of RGC
[44]. In the present study, using the DBA/2J mouse as a model
of inherited glaucoma, we demonstrate that TNF expression
increases with age in the retina and optic nerve, suggesting
that  TNF  may  contribute  to  the  pathophysiology  of  the
glaucoma.
IL-18 is a proinflammatory cytokine in the IL-1 family
[45,46], and is an important regulator of innate and acquired
immune  responses.  IL-18  appears  to  play  a  role  in  many
autoimmune  and  inflammatory  diseases,  including
rheumatoid  arthritis,  ischemic  renal  and  heart  disease,
atherosclerosis, and multiple sclerosis [47-50]. We previously
demonstrated  that  IL-18  gene  and  protein  expression  is
significantly  increased  with  age  in  iris/ciliary  body  and
aqueous humor of DBA/2J mice. IL-18 in the aqueous humor
of DBA/2J mice increases with age [21]. Our present study
demonstrates that IL-18 gene and protein expression increase
significantly with age in retina and optic nerve of DBA/2J
mice. These novel findings suggest a role for IL-18 in the
pathogenesis of glaucoma in this animal model.
GFAP is well known to be a sensitive marker of glial
activation  in  response  to  neural  injury  [51].  GFAP  is
expressed in the normal retina mainly in astrocytes, and is
localized to the vicinity of the inner limiting membrane and
nerve fiber layer. Müller cells do not normally express GFAP,
but  they  can  be  induced  to  increase  their  expression  in
response  to  injury  [52,53].  Glial  cell  activation  has  been
proposed as an important factor contributing to RGC death in
glaucoma [36,37]. GFAP immunoreactivity was increased in
Müller cells from the inner to the outer limiting membranes
in retina from rats with elevated intraocular pressure [37].
Optic  nerve  head  astrocytes  demonstrate  increased  GFAP
expression  in  glaucoma  and  under  conditions  of  elevated
Figure  5.  Increased  IL-18  gene  and
protein expression in retina and optic
nerve from DBA/2J mice. A: RT–PCR
analysis  shows  increased  IL-18  gene
expression in retina from DBA/2J mice
at  3  and  6  months  old.  B:  Graphical
representation  of  4  independent
experiments  in  A  normalized  with
GAPDH  loading  control  (mean±SD).
C:  Western  blot  of  IL-18  protein
expression in retina from DBA/2J mice
at 1 to 6 months of age. D: Densitometric
analysis of 3 independent experiments
from C, using actin as a loading control,
revealed significantly higher expression
of IL-18 in retina from DBA/2J mice
from 4 to 6 months when compared with
1 month of age. E: Western blot of IL-18
protein expression in optic nerve from
DBA/2J mice at 1 to 6 months of age.
F:  Densitometric  analysis  of  3
independent experiments from E, shows
increased  IL-18  protein  expression
compared  to  actin  loading  control  in
optic  nerve  from  DBA/2J  mice  by  5
months of age. Statistical analyses for
this  experiment  was  performed  using
ANOVA  with  the  Scheffé  multiple
comparison test (the asterisk indicates a
p<0.05).
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444hydrostatic  pressure  [54].  In  our  present  study,  GFAP
expression increased dramatically with age in retina and optic
nerve of DBA/2J mice. This finding is in agreement with the
view that activation of retinal glial cells is a prominent feature
of  the  glaucomatous  retina.  Furthermore,  it  has  been
demonstrated  that  activated  glial  cells  may  have  noxious
Figure 6. Localization of glial fibrillary acidic protein (GFAP) in retina and optic nerve from DBA/2J mice. A,B: Respective retina and optic
nerve sections from DBA/2J mice at 1 month of age show minimal staining for GFAP. C,D: Respective retina and optic nerve sections from
DBA/2J mice at 6 months of age show prominent immunostaining for GFAP in retinal Müller cells and optic nerve. E,F: western blot analysis
for GFAP protein in the retina and optic nerve, respectively. G,H: Densitometric analysis of 3 independent experiments from E and F, using
actin as a loading control. Statistical analyses for this experiment was performed using ANOVA with the Scheffé multiple comparison test
(the asterisk indicates a p<0.05).
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445effects  on  neuronal  tissue  by  alteration  of  the  neuron
microenvironment [14,55,56]. For example, activated glial
cells in glaucomatous eyes produce neurotoxic substances,
such as nitric oxide synthase and TNF [15,16]. These data
suggest that astrocytes and Müller cells may be important
contributors to the pathogenesis of glaucoma.
PEDF has neuroprotective and antiangiogenic functions
in the mammalian eye, and was recently shown to have anti-
inflammatory  properties  as  well.  PEDF  levels  in  vitreous
humor  are  decreased  in  patients  with  diabetes  and
proliferative  retinopathy  [57].  PEDF  treatment  decreased
retinal levels of proinflammatory cytokines in experimental
diabetes, suggesting a possible role as an endogenous anti-
inflammatory  factor  [10].  In  cultured  retinal  capillary
endothelial  cells,  PEDF  significantly  decreased  TNF
expression  due  to  hypoxia.  Moreover,  downregulation  of
PEDF expression by siRNA treatment of retinal Müller cells
resulted in significantly increased TNF expression [10,58].
PEDF levels in aqueous humor were significantly reduced in
advanced  glaucoma  as  compared  to  normal  controls  [8].
Pressure-induced ischemia and subsequent reperfusion led to
extensive  RGC  death  in  the  absence  of  PEDF,  whereas
addition of PEDF protected RGC [9,59]. In summary, the
published literature strongly supports a role for PEDF as an
anti-inflammatory molecule in a variety of ocular conditions.
The studies reported herein strongly suggest a role for
PEDF in the maintenance of RGC in the DBA/2J mouse model
of glaucoma, and add indirectly to the evidence for reduced
PEDF  as  a  possible  pathogenic  mechanism  in  human
glaucoma.  We  demonstrate  that  endogenous  PEDF
expression in retina and optic nerve of DBA/2J mice declines
with age, while PEDF transfection maintains RGC viability,
inhibits  TNF  and  IL-18  upregulation,  and  reduces  GFAP
expression. Our data suggest that PEDF may be involved in
the  pathogenesis  of  glaucoma  in  this  mouse  model,  that
decreased  PEDF  levels  in  aging  eyes  may  contribute  to
subclinical inflammation in glaucoma, and that the protective
effect  of  PEDF  on  glaucoma  in  DBA/2J  mice  may  be
mediated, at least in part, by its anti-inflammatory activity.
Development of glaucoma in DBA/2J mice takes months;
while the activity of PEDF applied by a periocular route is
approximately  6  h  [60].  Repeated  intravitreal  injection  of
PEDF would be impractical, but gene transfer in our model
was effective in the prevention of visual loss, and could be
Figure 7. PEDF gene transfection protects against the loss of RGC in DBA/2J mouse retina and delays vision loss. A: Retina flat whole-mount
shows extensive GFP labeling 9 months after transfection with AAV-GFP (at 11 months of age). B: Retina cross section shows GFP labeling
in ganglion cell layer and in inner nuclear layer. C: Western blot for PEDF in retina from DBA/2J mice 9 months after AAV-PEDF transfection.
D: Protection of RGC in DBA/2J mice retina 9 months after transfection with AAV-PEDF. E: RGC loss in retina 9 months after transfection
with AAV-GFP. Insets show higher magnification. F: Visual acuity in mock transfected, AAV-GFP, and AAV-PEDF transfected DBA/2J
mice, in comparison to C57BL/6J mice. Acuity decreased progressively beginning at 4 months of age (2 months post transfection) in control
transfected and AAV-GFP treated mice, but was maintained to age 11 months in AAV-PEDF transfected mice. Abbreviations: retinal ganglion
cell (RGC) layer; inner nuclear layer (INL).
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446considered in the prevention of human glaucoma. Our results
support a role for PEDF as a potent and efficacious agent to
reduce RGC death and vision loss in DBA/2J mice. An anti-
inflammatory approach to glaucoma, as illustrated by the use
of  PEDF,  represents  a  novel  advance  in  the  potential
prevention of glaucomatous RGC death.
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